Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and support the pharma-maker’s oncology portfolio and other therapeutic offerings.
As part of the agreement, Merck will leverage Tempus AI, Inc. (NASDAQ:TEM)’s de-identified data and Lens Platform and Workspaces technologies to generate new discoveries and accelerate the development and effective use of candidate therapies on a large scale.
In other news, on February 25, JPMorgan analyst Casey Woodring slashed the stock’s price target to $60 from $80, with a Neutral rating, following the company’s Q4 earnings call a day prior.
Photo from Iovance Biotherapeutics website
According to TipRanks, the firm cited Tempus AI, Inc.’s (NASDAQ:TEM) ‘clouded visibility’ on data upside and a revision to its outlook for Ambry as the reason behind the adjustment.
As of the close of business on March 4, the stock is a Moderate Buy, with an average upside potential of 52.5%.
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.
While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Magic Formula Stocks for 2026.
Disclosure: None. Follow Insider Monkey on Google News.
